Park Medi World Shares: Hospital Stock Falls 15% in a Month, Will the Stock Rebound? Experts Show Road Map to Investors on Supreme Court Drug Price Cap
- October 13, 2026
- Posted by: Lakshit Sharma
- Category: News
Park Medi World shares: about 15% below the Rs 305 high (my calculation, from the Rs 260 support zone), after a Supreme Court hearing on 12 Oct 2026 on a drug price cap. Next hearing: 27 Oct 2026. Company says oncology is under 2% of revenue. Choice Institutional Equities target: Rs 350.
Quick Answer
Park Medi World shares have fallen about 15% from their 52-week high of about Rs 305 to the Rs 260 support zone (my calculation), as hospital stocks reacted to a Supreme Court hearing on 12 October 2026 about capping drug prices and retailer margins. The company says oncology and chemotherapy are under 2% of its revenue, so it expects a negligible financial impact, and its average revenue per occupied bed is Rs 30,444. The next hearing is on 27 October 2026, and Choice Institutional Equities kept a Buy with a Rs 350 target in July. Watch the Rs 260 support and the Rs 305.25 high, and read the court outcome before you add.
Park Medi World shares came under pressure after the Supreme Court asked the government why drug prices and margins at hospitals should not be capped. The stock is the second-largest private hospital chain in North India, and it fell as much as 6% on 12 October along with Apollo, Max Healthcare, Fortis and Aster DM.
This guide covers the court hearing, how much of the business a drug price cap could touch, the price levels analysts and data pages are watching, the expansion plan behind the Rs 350 target and the risks. Sources differ on some price data, so I flag every conflict.
Anyone holding Park Medi World shares should separate the short term court headline from the long term bed expansion story.
Click Here – Get Free Investment Predictions
Why Park Medi World Shares Fell: The Supreme Court Drug Price Cap Hearing
| Date | Event | Detail |
|---|---|---|
| Earlier hearings | Court asks about a uniform margin | The court suggested a uniform 16% margin on medicines and called markups on cancer drugs at hospitals carnage |
| 12 Oct 2026 | Hearing on drug price cap | The government said it must balance pricing and availability and is not trying to control the entire drug market |
| 12 Oct 2026 | Hospital stocks fall | Park Medi World fell as much as 6%, Apollo and Max up to 3%, Fortis 3.5%, Aster DM 2.8% |
| 27 Oct 2026 | Next hearing | Scheduled |
The government has already capped trade margins at 30% on non-scheduled anti-cancer drugs, which sit outside the regular price control list. In 2019 the NPPA capped margins at 30% on 42 such drugs, and the government says this saved around Rs 984 crore a year.
Risk: A wider cap on drug margins could reduce pharmacy and consumables income at hospitals. The extent depends on what the court orders on 27 October, which no one can predict.
Compare hospital stocks on the Univest Screener
How Much Could a Drug Price Cap Hurt Park Medi World Shares?
The company said proposed caps on cancer and chemotherapy drug prices would have a negligible financial impact. Oncology and chemotherapy make up under 2% of total revenue, and management says it prioritises patient turnover over higher drug markups.
| Measure | Park Medi World | Large metro hospital networks |
|---|---|---|
| Average revenue per occupied bed (ARPOB) | Rs 30,444 | Rs 68,000 to Rs 82,000 |
| Oncology and chemotherapy share of revenue | Under 2% | Not stated |
| Revenue in FY26 | Rs 1,679 crore | Not stated |
A low ARPOB means the chain behind Park Medi World shares earns less per bed than metro peers, and that makes a drug margin cap less important to it. The same fact also shows why its growth comes from adding beds and not from higher pricing.
Download the Univest iOS App or Univest Android App to track Park Medi World shares and your watchlist.
Park Medi World Shares: Price Levels and Technical Picture
| Level | Value | Source note |
|---|---|---|
| 52-week high | Rs 305 to Rs 305.25 | Two sources, slightly different |
| Support | About Rs 260 | Data page |
| Latest close on a data page published 12 Oct | Rs 271, up 3.85% | Appears to be the previous session; conflicts with the 6% intraday fall reported on 12 Oct |
| Fall from Rs 305.25 to Rs 260 | About 14.8% | My calculation |
| Year to date return | About 85% | Data page |
| One month return | About negative 4% | Data page, which differs from the 15% in the headline |
The 15% in the headline matches a fall from the high near Rs 305 to about Rs 260 (my calculation), and not the one month return of about negative 4% that two data pages show. I could not verify the exact base the headline used. One page also lists a 52-week low of Rs 168.10 and another Rs 138.15, so treat the low as unverified.
The technical picture on one data page moved from mildly bearish to sideways. A move in Park Medi World shares above the Rs 305.25 high would confirm a breakout, while a break below Rs 260 would weaken the setup. Later headlines on the same page mention an intraday low and a lower circuit on 13 October, which I could not verify.
Risk: Price data on these pages conflicts, so check the live quote and the NSE data before you act on any level.
Will Park Medi World Shares Rebound? The Expansion Case
The bull case for Park Medi World shares rests on bed expansion. Choice Institutional Equities, in a July note, kept a Buy and a target price of Rs 350, about 20.6% above the trading level cited in that note. From the Rs 271 level it is about 29% (my calculation).
| Project | Detail |
|---|---|
| Long term goal | 10,000 beds by FY33, with about 5,590 beds expected by March 2028 |
| Gurugram | A 100-bed Park Hospital Platinum, expected by November 2026, capex about Rs 25 crore; Palam Vihar ran at about 86% occupancy in FY26 |
| Rudrapur, Uttarakhand | Acquisition of the 330-bed Medicity Hospital for Rs 177 crore |
| Prayagraj, Uttar Pradesh | A wholly owned subsidiary to build a 550-bed hospital under a public private partnership |
| Revenue outlook (broker) | From Rs 1,679 crore in FY26 to Rs 3,945 crore in FY29 |
The broker’s forecast for Park Medi World shares is an estimate and not a company guarantee, and new hospitals take time to fill. If the court outcome on 27 October is mild, the expansion story may take the lead again for Park Medi World shares.
What to Watch Next for Park Medi World Shares
- The Supreme Court hearing on 27 October 2026 and any order on margins or price caps.
- Whether Park Medi World shares hold the Rs 260 support.
- A close above the Rs 305.25 high for a breakout signal.
- Q2 FY27 results and occupancy and ARPOB trends.
- Progress on the Gurugram, Rudrapur and Prayagraj projects.
Conclusion
Park Medi World shares fell with the hospital sector on the Supreme Court drug price cap hearing, but the company says oncology is under 2% of revenue and its expansion plan points to Rs 350 in a Choice note. The next hearing on 27 October and the Rs 260 support are the next markers. Check live prices and the exchange filings before you decide.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Park Medi World shares fall?
Ans. Hospital stocks fell after a Supreme Court hearing on 12 October 2026 on capping drug prices and margins. Park Medi World fell as much as 6% that day, with Apollo, Max, Fortis and Aster DM also lower.
How much have Park Medi World shares fallen in a month?
Ans. The headline says 15%. That matches a fall from the high near Rs 305 to about Rs 260 (my calculation). Two data pages show a one month return of about negative 4%, so the base differs.
How much of Park Medi World’s revenue comes from cancer drugs?
Ans. Oncology and chemotherapy are under 2% of total revenue, and the company says a cap on cancer drug prices would have a negligible financial impact.
When is the next Supreme Court hearing on the drug price cap?
Ans. The next hearing is on 27 October 2026.
What is the target price for Park Medi World shares?
Ans. Choice Institutional Equities kept a Buy with a target price of Rs 350 in July 2026, about 20.6% above the trading level cited then. It is an analyst estimate, not a promise.
What are the key price levels for Park Medi World shares?
Ans. Support is near Rs 260 and the 52-week high is about Rs 305.25. A move above the high would confirm a breakout, according to a data page. Check the live quote.
What is the growth plan behind Park Medi World shares?
Ans. The company targets 10,000 beds by FY33, about 5,590 beds by March 2028, a 100-bed Gurugram hospital, a 330-bed Rudrapur acquisition and a 550-bed Prayagraj project.
Should I buy Park Medi World shares now?
Ans. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before you buy, sell or hold Park Medi World shares.